The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism
Joint Authors
Vargas, Guadalupe
Gonzalez, Baldomero
Mendoza, Victoria
Balcázar-Hernández, Lourdes Josefina
Pérez-Villarreal, Gabriel
Ramírez de Santiago, Andrés
Landa-Gutierrez, Oscar
Estrada-Robles, Carlos
Source
International Journal of Endocrinology
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-03
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Objective.
To evaluate cardiovascular risk, metabolic profile, low urinary tract symptoms (LUTS), and sexual function in patients with nonfunctional pituitary macroadenoma (NFPMA) and hypogonadotropic hypogonadism with testosterone therapy (TTh).
Methods.
A retrospective clinical study at a tertiary care center was performed in 101 men with NFPMA, HH, and TTh; metabolic profile, cardiovascular risk, International Prostate Symptoms Score (IPSS), and International Index of Erectile Function 5 (IIEF-5) scores were evaluated before initiation of TTh and at the last checkup with TTh.
Results.
Age was 49.3 ± 8.8 years; T before TTh was 195 ng/mL (101–259) vs.
574 (423–774) at the last checkup.
The time of TTh administration was 34 months (12–72).
An increase in triglyceride levels (200 (153–294) vs.
174 (134–233) mg/dL; p=0.03), dyslipidemia (40% vs.
52%; p=0.03), and MetS (25% vs.
34%; p=0.05) was corroborated.
A statistical difference in the Globorisk score and cardiovascular (CV) risk stratification was not found.
IIEF-5 score was 15.5 ± 6.5 vs.
17.8 ± 5.3 (p=0.11).
An improvement in penetration quality (2.0 ± 1.5 vs.
2.6 ± 1.3; p=0.05), erection after penetration (1.8 ± 1.2 vs.
2.5 ± 1.6; p=0.02), completion of intercourse (1.8 ± 1.2 vs.
2.4 ± 1.3; p=0.03), and satisfaction of sexual intercourse (1.8 ± 1.3 vs.
2.5 ± 1.5; p=0.01) was evidenced.
IPSS score was 6 (IQR 2–10) vs.
7 (IQR 4–12); p=0.30.
A lower rate of intermittency (14% vs.
3%; p=0.02), urgency (39% vs.
16%; p=0.01), and episodes of nocturia (18% vs.
4%; p=0.02) was found.
An increase of hematocrit (44.1 ± 4.4 vs.
47.3 ± 4.4%; p=0.001), hemoglobin (14.9 ± 1.4 vs.
15.9 ± 1.4 g/dL; p=0.001), and prostatic specific antigen (0.59 (0.43–1.19) vs.
0.82 (0.45–1.4) ng/mL; p=0.02) was evidenced during TTh.
Conclusion.
TTh in young men with NFPMA improves LUTS, sexual function, and some metabolic parameters, and it is relatively safe in the prostatic context.
American Psychological Association (APA)
Vargas, Guadalupe& Pérez-Villarreal, Gabriel& Ramírez de Santiago, Andrés& Balcázar-Hernández, Lourdes Josefina& Mendoza, Victoria& Landa-Gutierrez, Oscar…[et al.]. 2019. The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism. International Journal of Endocrinology،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1159390
Modern Language Association (MLA)
Vargas, Guadalupe…[et al.]. The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism. International Journal of Endocrinology No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1159390
American Medical Association (AMA)
Vargas, Guadalupe& Pérez-Villarreal, Gabriel& Ramírez de Santiago, Andrés& Balcázar-Hernández, Lourdes Josefina& Mendoza, Victoria& Landa-Gutierrez, Oscar…[et al.]. The Testosterone Effect on Metabolic and Urologic Outcomes in Patients with Nonfunctioning Pituitary Macroadenomas and Hypogonadotropic Hypogonadism. International Journal of Endocrinology. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1159390
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1159390